REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

RegulatoryRGX-121Neutral

AI Analysis

Summary

REGENXBIO announced a regulatory update on RGX-121 (clemidsogene lanparvovec), an investigational gene therapy for Mucopolysaccharidosis type II, though the article is truncated and specific details of the update are not provided.

Importance:4/10

Sentiment:

0.00

gene therapyregulatory updaterare diseaseMPS IIFDA

Related Companies

$RGNX

Read the original article

Published by PR Newswire Clinical Trials on August 24, 2026 11:05 AM

Read Original